Drugs / CAR-T cell
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT07040917 | Sep 2025 → Nov 2027 expected | autoimmune disease | Chinese PLA General Hospital | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT06762119 | Jan 2025 → Aug 2027 expected | autoimmune disease | Zhejiang University | Not yet recruiting | No outcome recorded |
| Phase 12 trials | ||||||
| Phase 1 | NCT05003895 | Dec 2021 → Dec 2026 expected | hepatocellular carcinoma | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
| Phase 1 | NCT04121273 | Oct 2019 → Oct 2021 | hepatocellular carcinoma | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Unknown | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02959151 | Jul 2016 → Jan 2018 | colorectal cancer, hepatocellular carcinoma, malignant pancreatic neoplasm | Shanghai GeneChem Co., Ltd. | Unknown | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT06900764 | Oct 2025 → Nov 2027 expected | systemic lupus erythematosus | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Not yet recruiting | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06768905 Background | Apr 2025 → May 2029 expected | diffuse large B-cell lymphoma | University of Texas Southwestern Medical Center | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CAR-T cell | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02959151 ↗ |
| Action | Deplete | “The gene will introduce into T cell from patient's blood to make them recognize and kill cancer cells.” NCT04121273 ↗ |
| Modality | Cell therapy | “CAR-T cells are generated by T cells from the patients or a suitable donor transfected by CAR-lentivirus vectors.” NCT02959151 ↗ |
| Route | Other | “administered by vascular interventional therapy or by intra-tumor injection” NCT02959151 ↗ |
| Target | GPC3 | “CAR-T cells targeting GPC3 will be administered to enrolled patients with hepatocellular carcinoma.” NCT04121273 ↗ |